<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02994485</url>
  </required_header>
  <id_info>
    <org_study_id>Nadia Elwan</org_study_id>
    <nct_id>NCT02994485</nct_id>
  </id_info>
  <brief_title>Evaluation Of The Portal Pressure By Doppler Ultrasound In Cirrhotic Patients Before And After Simvastatin</brief_title>
  <official_title>Evaluation Of The Portal Pressure By Doppler Ultrasound In Cirrhotic Patients Before And After Simvastatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Portal hypertension is not a disease in itself. Rather, it is an indication of an illness,
      caused mostly by chronic lesions of the liver because of distinct causes, such as viral
      infection, chronic alcoholism, or metabolic disorders. Other reasons include splanchnic
      vascular diseases (for example, obstruction of the portal or the hepatic veins). Portal
      hypertension is defined as a pressure in the portal vein exceeding the vena cava pressure by
      more than 5 mm Hg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Indeed, use of simvastatin might attenuate liver fibrosis in patients with chronic C
      infection, it may also reduce hepatic vascular resistance and portal pressure by improving
      liver generation of nitric oxide and hepatic endothelial dysfunction in patients with
      cirrhosis, so it could be an effective therapy for portal hypertension. It might even improve
      survival of patients with cirrhosis after variceal bleeding.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients with Reduced Portal Pressure After Intervention</measure>
    <time_frame>6 Months</time_frame>
    <description>the number of Patients with Reduced Portal Pressure After Intervention</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks plus the routine treatment</description>
    <arm_group_label>Simvastatin</arm_group_label>
    <other_name>Corvast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive diagnosis of cirrhosis by US (coarse echogenic pattern, bulky caudate lobe,
             attenuated hepatic veins)

          -  Clinical manifestations of portal hypertension (as esophageal varices ,splenomegaly,
             ascites and encephalopathy grade I-II)

        Exclusion Criteria:

          -  Pregnancy

          -  Hepatic encephalopathy grade III-IV

          -  Hepatocellular carcinoma

          -  Treatment with statins in the previous 3 months

          -  Hypersensitivity to statins

          -  Previous surgical shunt or TIPS

          -  Treatment with calcium channel blockers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NADIA ELWAN, PROFESSOR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tanta university hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>RAAFAT SALAH, PROFESSOR</last_name>
    <role>Study Chair</role>
    <affiliation>Tanta university hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MANAL HAMISA, Ass Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Tanta university hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>EBTESAM A SHADY, BACHELOR</last_name>
    <role>Study Chair</role>
    <affiliation>Tanta University hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sherief Abd-Elsalam</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2016</study_first_submitted>
  <study_first_submitted_qc>December 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2016</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sherief Abd-Elsalam</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

